[Combined use of pyronaridine, sulfadoxine and primaquine in areas with chloroquine-resistant falciparum malaria].
Che
L G
LG
Huang
K G
KG
Yang
H L
HL
Yu
L
L
Lin
Z L
ZL
Huang
R
R
D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D002738:Chloroquine / Q000494:pharmacology; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D009287:Naphthyridines / Q000008:administration & dosage*; D010963:Plasmodium falciparum / Q000187:drug effects; D011319:Primaquine / Q000008:administration & dosage*; D013413:Sulfadoxine / Q000008:administration & dosage*; D013424:Sulfanilamides / Q000008:administration & dosage*
D000962:Antimalarials; D009287:Naphthyridines; D013424:Sulfanilamides; D013413:Sulfadoxine; D002738:Chloroquine; D011319:Primaquine; C027871:pyronaridine